免费看一级做a爰片_MM1313又粗又大受不了_午夜男女免费永久免费视频_亚洲香蕉久久_欧美三级毛片在线高清_国产污污污十八在线精品观看_亚洲经典中文字幕欧美_苍井空一区二区三区_日本三级吃奶乳视频在线播放_日韩黄色软件

Ms. Gong is responsible for the overall strategy, business direction of our Company.

Ms. Gong was previously worked for Credit Suisse First Boston, Global Infrastructure Partners LLP, Deutsche Bank, Anbang Insurance and other well-known investment banks and investment institutions. In 2019, she founded the Guizhou Province Xiao Yingying Charity Foundation.

In 2019, Ms. Gong was elected as one of the nine Young Global Leaders from the Greater China region by the World Economic Forum. She received the bachelor’s degree in economics from the London School of Economics and Political Science and the Executive Master of Business Administration degree from Cheung Kong Graduate School of Business

Mr. Xu is responsible for implementation of the overall strategy, business direction and management of our Company. Mr. Xu has served as the deputy director of the Tsinghua University—YiduCloud Intelligent Automated Medical System Joint Research Center since May 2018.

Mr. Xu has over ten years of experience in the fields of search engine technology, big data and AI. Before joining our Group, Mr. Xu worked in the mobile business division of Alibaba where he held the positions of senior architect at UCWeb and general manager of the search product technology center of amap.com. Before that, Mr.Xu worked at Baidu Internet Technology.

Mr. Xu received a master’s degree in computer application technology from the Graduate School of the Chinese Academy of Sciences and a bachelor’s degree in automation from Tsinghua University.

Ms. Feng oversees the finance, the investing and financing activities of our Company, and managing the day-to-day operations.

Ms. Feng has worked at PricewaterhouseCoopers, Deloitte, China Minsheng Investment Group, OFO and other institutions. Ms. Feng is a Chartered Professional Accountant of Canada and a Certified Public Accountant of China.

Ms. Feng obtained her Bachelor degree in Management from the School of Economics and Management of the Tsinghua University.

Dr. Xie Li has served as the Head of Innovative Medicine and Real-World Evidence Department at Tianjin Happy Life Technology Co., Ltd., a subsidiary of the Company, since May 2022.

Dr. Xie has nearly ten years of experience as a clinical doctor and more than ten years of working experience in the medical affairs, health economics, and outcomes research departments at top ten multinational pharmaceutical companies, and serves as a member of the Professional Committee on Pharmaceutical Policy and Evaluation of the National Association of Health Industry and Enterprise Management (全國(guó)衛(wèi)生產(chǎn)業(yè)企業(yè)管理協(xié)會(huì)醫(yī)藥政策與評(píng)價(jià)專(zhuān)業(yè)委員會(huì)) and an external expert at the China-Australia Joint Research Center for Infectious Diseases jointly established by Monash University in Australia and Xi’an Jiaotong University Health Science Centre (西安交通大學(xué)醫(yī)學(xué)部). She has supported the launch of the most successful pharmaceutical products in China and several first-in-class drugs, as well as market access work including medical insurance negotiations, centralized procurement, and commercial insurance. Dr. Xie has extensive industry experience in the medical, pharmaceutical, and health insurance fields. Her major research areas focus on real-world studies and health economics research, collaboration with research institutes and pharmaceutical and medical device companies to promote the application of AI and big data in healthcare and health insurance.

Dr. Xie was the awardee of the scientific and technological second prize of Shaanxi Province and the recipient of multiple research grants. She collaborated with research institutions including Shanghai Fudan University, Peking University, Capital Medical University, the Health Development Research Center of the National Health Commission (衛(wèi)健委衛(wèi)發(fā)中心), and the Shanghai Health Development Research Center (上海衛(wèi)發(fā)中心) and jointly published the ‘‘Research Report on the Value Evaluation and Practical Application of High-Value Medical Consumables (《高值醫(yī)用耗材價(jià)值評(píng)估與實(shí)踐應(yīng)用研究報(bào)告》)’’, which is the most complete evaluation system of high-value medical consumables with the most comprehensive value dimension in China, and has published over 20 papers in renowned academic journals and conferences, including the Journal of Hepatology, Hepatology, JAMA Network Open, and ISPOR.

Dr. Xie obtained her Doctor of Medicine degree from Xi’an Jiaotong University in December 2019.

Mr. Zeng has been appointed as a non-executive director of the Company with effect from 25 June 2021.

Mr. Zeng was appointed as an independent non-executive director of Longfor Group Holdings Limited (a company whose shares are listed on The Stock Exchange of Hong Kong Limited, stock code: 960) on 3 June 2011. He is also the chairman of the remuneration committee of Longfor Group Holdings Limited. Mr. Zeng was the chief strategy officer of Alibaba Group between 2006 and 2018. Mr. Zeng has published a number of books on business strategies.

Mr. Zeng obtained his Doctor of Philosophy degree in International Business and Strategy from University of Illinois at Urbana-Champaign, USA in 1998 and a Bachelor of Arts degree in Economics from Fudan University in 1991. Mr. Zeng was the professor of Strategy at Cheung Kong Graduate School of Business, Beijing China and a faculty member at INSEAD, France.

Dr. Ma has served as a vice president and the head of the AI Laboratory at ByteDance, where he is responsible for the fundamental research and technology development in the fields of, among others, machine learning, computer vision, speech and audio processing, natural language processing and personalized recommendation and search engine. Before joining ByteDance, Dr. Ma worked at Microsoft Research Asia as assistant managing director. Dr. Ma has also served as a guest professor in computer science at National Taiwan University.

Dr. Ma has over 160 granted patents and has published more than 300 papers in prestigious international journals and conferences, including various IEEE publications and the International Conference on World Wide Web (WWW). He served on the editorial boards of several professional journals including ACM Transactions on Information System, and co-chaired many international conferences. Dr. Ma was accredited as a fellow of the IEEE in 2011 and a Distinguished Scientist by ACM in 2010.

Dr. Ma holds a Ph.D. and a master’s degree in electrical and computer engineering from the University of California, Santa Barbara and received a bachelor’s degree in electrical engineering from National Tsing Hua University.

Ms. Pan Rongrong (CPA) has been the chief financial officer and a vice president of finance at SciClone Pharmaceuticals Group. Before that, Ms. Pan was a partner at PricewaterhouseCoopers.

Ms. Pan received a master’s degree in accounting from Fudan University and a bachelor’s degree in international accounting from Shanghai International Studies University.

Prof. Zhang has been a professor of microbiology and infectious diseases at the School of Medicine, Tsinghua University since 2008. Between 2014-2015, Prof. Zhang also served the role of Deputy Dean at the School of Medicine, Tsinghua University. Before joining TsingHua University, Prof. Zhang worked at the Aaron Diamond AIDS Research Center of the Rockefeller University as an associate professor.

Prof. Zhang has over 30 years of experience researching the pathogenesis of major human viral diseases and vaccine development. he has published over 80 papers in leading academic journals including Nature, New England Journal of Medicine, Nature Medicine and Journal of Clinical Investigation. He is the recipient of multiple national awards in China, including the National Science and Technology Awards second prize in 2015 and Distinguished Young Scholar of National Natural Science Foundation in 2008. He has also served as an expert member of national advisory boards of the PRC government and several international organizations on HIV/AIDS and infectious diseases and was elected a foreign fellow of the African Academy of Sciences in 2016

Prof. Zhang holds a Ph.D. from the University of Edinburgh and received a bachelor’s degree in biology from the Beijing Normal University.

Ms. Gong is responsible for the overall strategy, business direction of our Company.

Ms. Gong was previously worked for Credit Suisse First Boston, Global Infrastructure Partners LLP, Deutsche Bank, Anbang Insurance and other well-known investment banks and investment institutions. In 2019, she founded the Guizhou Province Xiao Yingying Charity Foundation.

In 2019, Ms. Gong was elected as one of the nine Young Global Leaders from the Greater China region by the World Economic Forum. She received the bachelor’s degree in economics from the London School of Economics and Political Science and the Executive Master of Business Administration degree from Cheung Kong Graduate School of Business.

Mr. Xu is responsible for implementation of the overall strategy, business direction and management of our Company. Mr. Xu has served as the deputy director of the Tsinghua University—YiduCloud Intelligent Automated Medical System Joint Research Center since May 2018.

Mr. Xu has over ten years of experience in the fields of search engine technology, big data and AI. Before joining our Group, Mr. Xu worked in the mobile business division of Alibaba where he held the positions of senior architect at UCWeb and general manager of the search product technology center of amap.com. Before that, Mr.Xu worked at Baidu Internet Technology.

Mr. Xu received a master’s degree in computer application technology from the Graduate School of the Chinese Academy of Sciences and a bachelor’s degree in automation from Tsinghua University.

Dr. Yan is responsible for the overall technology strategy of our Group, research and development of natural language processing and medical AI technologies and development and management of the technologies for Big Data Platform and Solutions products.

Dr. Yan worked at Microsoft (China) between July 2006 and November 2017 in various research roles, including as a senior lead researcher in the enterprise intelligence and data mining area. His main research areas included AI knowledge mining, knowledge-based machine learning, text processing technology, information retrieval and internet advertising with an emphasis on AI technologies in the medical field.

Dr. Yan has published over 80 papers in prestigious academic publications and conferences，and has been a member of the medical health and biological information processing committee of Chinese Information Processing Society of China since December 2018. Dr. Yan also chaired the organizing committee of the Global Artificial Intelligence Technology Conference and was invited as a special forum guest in 2018.

Dr. Yan holds a Ph.D. in applied mathematics from Peking University and received his bachelor’s degree in computational mathematics from Jilin University.

Ms. Feng oversees the finance, the investing and financing activities of our Company, and managing the day-to-day operations.

Ms. Feng has worked at PricewaterhouseCoopers, Deloitte, China Minsheng Investment Group, OFO and other institutions. Ms. Feng is a Chartered Professional Accountant of Canada and a Certified Public Accountant of China.

Ms. Feng obtained her Bachelor degree in Management from the School of Economics and Management of the Tsinghua University.

Dr. Xie Li has served as the Head of Innovative Medicine and Real-World Evidence Department at Tianjin Happy Life Technology Co., Ltd., a subsidiary of the Company, since May 2022.

Dr. Xie has nearly ten years of experience as a clinical doctor and more than ten years of working experience in the medical affairs, health economics, and outcomes research departments at top ten multinational pharmaceutical companies, and serves as a member of the Professional Committee on Pharmaceutical Policy and Evaluation of the National Association of Health Industry and Enterprise Management (全國(guó)衛(wèi)生產(chǎn)業(yè)企業(yè)管理協(xié)會(huì)醫(yī)藥政策與評(píng)價(jià)專(zhuān)業(yè)委員會(huì)) and an external expert at the China-Australia Joint Research Center for Infectious Diseases jointly established by Monash University in Australia and Xi’an Jiaotong University Health Science Centre (西安交通大學(xué)醫(yī)學(xué)部). She has supported the launch of the most successful pharmaceutical products in China and several first-in-class drugs, as well as market access work including medical insurance negotiations, centralized procurement, and commercial insurance. Dr. Xie has extensive industry experience in the medical, pharmaceutical, and health insurance fields. Her major research areas focus on real-world studies and health economics research, collaboration with research institutes and pharmaceutical and medical device companies to promote the application of AI and big data in healthcare and health insurance.

Dr. Xie was the awardee of the scientific and technological second prize of Shaanxi Province and the recipient of multiple research grants. She collaborated with research institutions including Shanghai Fudan University, Peking University, Capital Medical University, the Health Development Research Center of the National Health Commission (衛(wèi)健委衛(wèi)發(fā)中心), and the Shanghai Health Development Research Center (上海衛(wèi)發(fā)中心) and jointly published the ‘‘Research Report on the Value Evaluation and Practical Application of High-Value Medical Consumables (《高值醫(yī)用耗材價(jià)值評(píng)估與實(shí)踐應(yīng)用研究報(bào)告》)’’, which is the most complete evaluation system of high-value medical consumables with the most comprehensive value dimension in China, and has published over 20 papers in renowned academic journals and conferences, including the Journal of Hepatology, Hepatology, JAMA Network Open, and ISPOR.

Dr. Xie obtained her Doctor of Medicine degree from Xi’an Jiaotong University in December 2019.